Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).

Abstract

Activation of the Raf-MEK-ERK signal transduction pathway in endothelial cells is required for angiogenesis. Raf is the kinase most efficiently inhibited by the multikinase inhibitor sorafenib, which has shown activity against certain human cancers in clinical trials. To understand the mechanisms underlying this activity, we studied how it controlled growth… (More)

Topics

Cite this paper

@article{Murphy2006InhibitionOT, title={Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).}, author={Danielle A. Murphy and Sosina Makonnen and Wiem Lassoued and Michael D. Feldman and Christopher David Carter and William M. F. Lee}, journal={The American journal of pathology}, year={2006}, volume={169 5}, pages={1875-85} }